Cite
HARVARD Citation
Bertho, M. et al. (2021). A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer. Expert opinion on drug metabolism and toxicology. pp. 139-152. [Online].